Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
3 Cards in this Set
- Front
- Back
|
Varubi's indication |
VARUBI is a substance P/neurokinkinin 1 (NK1) receptor antagonist indicated in combination with other antiemetic agents in adults for the prevention of Delayed nausea and vomiting associated with the initial and repeat causes entire of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. |
|
|
Dose of Varubi |
180mg rolapitant administered approximately 1 to 2 hours prior to the start of chemotherapy Administer in combination with dexamethasone and a 5ht3 receptor antagonist |
|
|
Section 12.1 of Varubi P.I. Explain MOA of Varubi |
Rolapitant is a selective & competitive antagonist of human substance P/NK1 receptors. Rolapitant does not have significant affinity for NK2 or NK3 receptors or for a battery of other receptors, transporters, enzymes, and ion channels. Rolapitant is also active in animal models of chemotherapy -induced emesis. |
